miRNA-155 and application of its inhibitor in DC-CIK cell culture

A technology of mirna-155, 1. mirna-155, applied in the field of immunization, can solve the problems of unsatisfactory effect and poor efficacy of adoptive immunization

Active Publication Date: 2017-05-31
朗姿赛尔生物科技(广州)有限公司
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although a large number of studies have shown that DCs, DC tumor vaccines, and CIK cells have significant anti-tumor effects, clinical applications have found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • miRNA-155 and application of its inhibitor in DC-CIK cell culture
  • miRNA-155 and application of its inhibitor in DC-CIK cell culture
  • miRNA-155 and application of its inhibitor in DC-CIK cell culture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: The effect of miRNA-155 on DC-CIK cell co-culture

[0025] 1. Experimental materials

[0026] 1. miRNA-155 inhibitor is provided by Shanghai Jima Pharmaceutical Technology Co., Ltd. (sequence 1 below); inhibitor negative control is provided by Shanghai Jima Pharmaceutical Technology Co., Ltd. (sequence 2 below).

[0027] Sequence 1: 5’-ACCCCUAUCACGAUUAGCAUUAA-3’;

[0028] Sequence 2: 5’-CAGUACUUUUGUGUAGUACAA-3’.

[0029] 2. The tumor cells are leukemia cells, including K562 / A02, THP-1 and HL-60 cells.

[0030] 2. Experimental method

[0031] 1. The separation and culture of effector cells DC and CIK

[0032] (1) Separation of mononuclear cells: Collect 20mL of peripheral blood from healthy volunteers, dilute 1:1 with pre-cooled PBS, slowly add the upper layer of lymphocyte separation solution, 650g, centrifuge for 20min at 4°C, collect white cell layer, and separate mononuclear cells , Resuspend the cells in 1640 medium and place them at 37℃, 5% CO 2 Incubate for 2h in t...

Embodiment 2

[0082] Example 2: Screening of miRNA-155 inhibitors (Pseudostellaria japonicus B, C)

[0083] 1. Experimental materials

[0084] Pseudoginsenopsis cyclic peptide B was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; Pseudoginsenopsis cyclic peptide C was purchased from Kunming Institute of Botany, Chinese Academy of Sciences. Other materials are the same as in Example 1.

[0085] 2. Experimental method

[0086] 1. The separation and culture of effector cells DC and CIK

[0087] (1) Separation of mononuclear cells: Collect 20mL of peripheral blood from healthy volunteers, dilute 1:1 with pre-cooled PBS, slowly add the upper layer of lymphocyte separation solution, 650g, centrifuge for 20min at 4°C, collect white cell layer, and separate mononuclear cells , Resuspend the cells in 1640 medium and place them at 37℃, 5% CO 2 Incubate for 2h in the incubator.

[0088] (2) Cultivation of DC cells: After mononuclear cells are cultured for 2 hours, adherent cells are collected and induc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a miRNA-155 and an application of its inhibitor in a DC-CIK cell culture; the miRNA-155 can be used as a drug target and applied to improve the killability of a CIK cell co-cultured and enhanced by a DC cell to a cancer cell. The applicant study finds that the DC-CIK cell under down-regulated expression of miRNA-155 has higher killability than the DC-CIK cell under normal expression of miRNA-155, and the killability of the DC cell under down-regulated expression of miRNA-155 is basically consistent with the killability of the DC cell under the normal expression of miRNA-155, there is no significant difference. It indicates that the miRNA-155 down-regulation cannot directly improve the killability of the DC cell to leukemia cell, but the down-regulated DC cell of the miRNA-155 can significantly enhance the killability of the cancer cell through co-culture. The applicant further finds that radix pseudostellariae cyclic peptide B and radix pseudostellariae cyclic peptide C are effective inhibitors of miRNA-155.

Description

Technical field [0001] The invention belongs to the field of immunity, relates to the cultivation of DC-CIK cells, and specifically relates to the application of miRNA-155 and its inhibitors in the cultivation of DC-CIK cells. Background technique [0002] Biological immunotherapy is to supplement, induce or activate the inherent biological response regulation system in the body from outside, activate and mobilize biologically active cells and cytokines with cytotoxic activity to adjust various immune-killing biological responses. At present, there are more research applications in immunotherapy: lymphokine-activated killer cells, tumor infiltrating lymphocytes, cytokine-induced killer (CIK) cells, dendritic cells (DC), and co-cultured immune (DC-CIK) cells , Natural killer cell type lymphocytes, among which DC and CIK cells are two important parts of tumor immunotherapy. The immune response induced by their interaction is the central link of the immunosuppressive effect [Wang Zh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0783
CPCC12N5/0638C12N2501/65C12N2502/1121
Inventor 不公告发明人
Owner 朗姿赛尔生物科技(广州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap